FDA/NIH program supports regulatory innovations
This article was originally published in The Tan Sheet
FDA and the National Institutes of Health launch a grant program to upgrade FDA's regulatory science, seeking proposals from academic institutions or non-profits interested in developing innovative approaches for reviewing applications for new medical products - including drugs, biologics and devices - and new ways of monitoring product safety and manufacturing processes. The program, announced Feb. 24, is FDA Commissioner Margaret Hamburg's latest effort to upgrade the agency's capacity to evaluate drug and device development programs. Existing agency budgets will fund the three-year, $6.75 million program, with 89 percent from NIH. The Obama administration requested $25 million to improve regulatory science capacity at FDA for fiscal 2011
You may also be interested in...
The National Institutes of Health will look at investing more in regulatory science if the academic and nonprofit research community shows strong interest in the $6.75 million research program NIH and FDA are funding
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.